One hundred and four-week real-world effectiveness of deucravacitinib 6 mg for genital, scalp, and nail psoriasis: A prospective study in Japan - 18/06/26
Doi : 10.1016/j.jaad.2026.02.103
Teppei Hagino, MD, PhD a, ⁎ 
, Hidehisa Saeki, MD, PhD b, Eita Fujimoto, MD, PhD c, Naoko Kanda, MD, PhD a
, Hidehisa Saeki, MD, PhD b, Eita Fujimoto, MD, PhD c, Naoko Kanda, MD, PhD a a Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan
b Department of Dermatology, Nippon Medical School, Tokyo, Japan
c Department of Dermatology, Fujimoto Dermatology Clinic, Funabashi, Japan
∗ Correspondence to: Teppei Hagino, MD, PhD, Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Kamagari 1715, Inzai, Chiba 270-1694, Japan Department of Dermatology Nippon Medical School Chiba Hokusoh Hospital Kamagari 1715 Inzai Chiba 270-1694 Japan
Key words : psoriasis, deucravacitinib, effectiveness, difficult-to-treat areas, real world
| Funding sources: None. |
|
| IRB approval status: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of Nippon Medical School Chiba Hokusoh Hospital. |
© 2026
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 95 - N° 1
P. 214-216 - juillet 2026 Retour au numéro
Article précédent
- Risk and protective factors for uveal melanoma: Evidence for a protective role of autoimmune and immune-mediated conditions
- Charles Lu, Debby Cheng, Andrew Mu, Olivia Burke, Lirit Fuksman, Priya Katyal, Sara Khattab, Nga Nguyen, Emma Beagles, Crystal Chang, Suzanne Xu, Jonathan C. Hwang, Linden Huhmann, Nicholas Starink, Martin A. Weinstock, Maryam M. Asgari, Marc S. Hurlbert, John M. Gaziano, Nathanael R. Fillmore, Rebecca I. Hartman, Yevgeniy R. Semenov
- A retrospective study of 308 Chinese nevus simplex patients: A nomogram predicting natural regression over time
- Xiaoxue Xing, Qinyi Chen, Yaqi Dong, Yijian Zhu, Chengfeng Zhang, Fang Yan, Zhong Lu, Leihong Xiang, Hui Qian, Jie Ren
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?